Navigation Links
Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
Date:8/12/2008

treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska plans to submit the revised Phase 3 clinical trial to the FDA for Special Protocol Assessment (SPA) procedure approval, Duska believes that the initial dose of ATPace(TM) will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT, ATP is believed to have dual inhibitory action; one mediated by adenosine, the product of its rapid enzymatic degradation, and the other, a triggered vagal reflex, Duska intends to initiate a single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with PSVT to demonstrate ATPace's clinical safety and efficacy, Duska intends to file a New Drug Application under section 505(b)(2), Dr. Amir Pelleg believes that the comments of
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
2. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
(Date:7/27/2014)... European Bromine market report defines and segments the Bromine market ... market in European region comprises of four major countries. They ... forms a dominant share of Bromine market influences the demand ... through the TOC of the Europe Bromine Market report, to ... the TOC of the Europe Bromine Market report. The report ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... muscle, bone behind severity of damage, longer recovery, study finds ... muscles of the lower body appear to be more vulnerable ... new study suggests. , The study analyzed the weight and ... over a three-year period. Sprains, such as to the ankle ...
... ranked among the top competitors in the world for Biathlon competitions. As ... Games to be held in Vancouver, Canada. Lanny and Tracy are crediting ... helping them get the most out of their training. , ... Parsippany, ...
... from Sticky Jewelry make a difference. Sticky J attends the "Walk ... and the Juvenile Diabetes Research Foundation made the day a success. ... ... 2000 Sticky Jewelry (StickyJ.com) has specialized in selling personalized jewelry ...
... of swine flu casesBELIZE CITY, Belize, May 1 ... residents and travelers against the swine flu, which is now ... additional proactive steps towards protection against the pandemic. ... Zone and casinos in the town of Corozal, which borders ...
... SCARBOROUGH, Maine , May 1, Binax, ... diagnostic tests to identify the causative pathogens of infectious ... information has been distributed to customers and potential customers of ... of the BinaxNow(R) Influenza A & B test has not ...
... with cancer that is resistant to standard therapy is the ... obtained in some settings, in many cases the therapies have ... has now been uncovered by a team of researchers, led ... London School of Medicine and Dentistry, London. , In the ...
Cached Medicine News:Health News:Obese Children More Likely to Suffer Lower Body Injuries 2Health News:Twin Sisters Set Their Sights On Biathlon Gold At The 2010 Winter Games 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 3Health News:Belize Takes Further Action Regarding Influenza A (H1N1) to Ensure Safety of Travelers 2
(Date:7/28/2014)... und LONDON , July ... , Ziel der Zusammenarbeit sind Entwicklung und Kommerzialisierung ... Plasmaproben zur Steuerung von Therapien mit IRESSA bei ... Neuer Bluttest basiert auf QIAGENs von der ... Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, laufen  ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... Receiving the herpes zoster vaccine was associated with a ... Kaiser Permanente study of 300,000 people that appears in the ... Association . This retrospective study observed the outcomes ... large, diverse population of men and women ages 60 years ...
... 11, 2011 Celleration, Inc., a privately held medical ... products, today announced the closing of an $8 million ... Company,s existing institutional investors participated in this round in ... a new investor. "The addition of ...
Cached Medicine Technology:Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 2Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 3Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 4
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Anatomical implants for the entire hand, in five sizes...
... a brief magnetic pulse to stimulate deep ... in Magnetic Nerve Stimulators. Based upon equipment ... in 1985. A powerful monophasic stimulator for ... best stimulator for Central Motor Conduction Studies, ...
Medicine Products: